Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jun 9, 2021
Date Accepted: Feb 16, 2022

The final, peer-reviewed published version of this preprint can be found here:

Review and Analysis of German Mobile Apps for Inflammatory Bowel Disease Management Using the Mobile Application Rating Scale: Systematic Search in App Stores and Content Analysis

Gerner M, Vuillerme N, Aubourg T, Messner EM, Terhorst Y, Hörmann V, Ganzleben I, Schenker H, Schett G, Atreya R, Neurath MF, Knitza J, Orlemann T

Review and Analysis of German Mobile Apps for Inflammatory Bowel Disease Management Using the Mobile Application Rating Scale: Systematic Search in App Stores and Content Analysis

JMIR Mhealth Uhealth 2022;10(5):e31102

DOI: 10.2196/31102

PMID: 35503246

PMCID: 9115651

German Mobile Apps for Inflammatory Bowel Disease Management: Review and Analysis using the Mobile Application Rating Scale (MARS)

  • Maximilian Gerner; 
  • Nicolas Vuillerme; 
  • Timothée Aubourg; 
  • Eva-Maria Messner; 
  • Yannik Terhorst; 
  • Verena Hörmann; 
  • Ingo Ganzleben; 
  • Hannah Schenker; 
  • Georg Schett; 
  • Raja Atreya; 
  • Markus F. Neurath; 
  • Johannes Knitza; 
  • Till Orlemann

ABSTRACT

Background:

Patients suffering from inflammatory bowel diseases (IBD) frequently need long-term medical treatment. Mobile apps promise to complement and improve IBD management, however, so far there is no scientific analysis of their quality.

Objective:

To evaluate the quality of German IBD mobile apps targeting inflammatory bowel disease patients and physicians treating IBD patients using the Mobile Application Rating Scale (MARS).

Methods:

The German Apple App Store and Google Play store were systematically searched to identify German IBD mobile apps for patients and physician use. MARS was used to independently assess app quality by 6 physicians, 3 using Android and 3 using iOS smartphones. Apps were randomly assigned so that the 4 apps with the most downloads were rated by all raters and the remaining apps were rated by 1 Android and 1 iOS user.

Results:

In total, we identified 1764 apps in the Apple App Store and Google Play Store. After removing apps that were not related to IBD (1386) and not available in German (317), 61 apps remained. After removing duplicates (3), congress (7), journal (4), and clinical study apps (6), as well as excluding apps that were available in only one of the two app stores (20) and apps which can only be used with an additional device (7) , 14 apps fulfilled the inclusion criteria. The app “CED Dokumentation und Tipps” had the highest overall MARS score with 4.11/5. Median MARS scores of the 14 apps were ranging from 2.38 and 4.11. All of the analyzed apps addressed patients. Three apps are classified as medical products. There was no significant difference between iOS and Android raters.

Conclusions:

The quality of German IBD apps is largely heterogeneous. Furthermore, despite promising international study results, little evidence exists proving a clinical benefit for German IBD apps. MARS seems to be a suitable method to identify relevant apps. Accordingly, clinical studies and also patient inclusion in the app development process are needed to effectively implement mobile apps in routine care.


 Citation

Please cite as:

Gerner M, Vuillerme N, Aubourg T, Messner EM, Terhorst Y, Hörmann V, Ganzleben I, Schenker H, Schett G, Atreya R, Neurath MF, Knitza J, Orlemann T

Review and Analysis of German Mobile Apps for Inflammatory Bowel Disease Management Using the Mobile Application Rating Scale: Systematic Search in App Stores and Content Analysis

JMIR Mhealth Uhealth 2022;10(5):e31102

DOI: 10.2196/31102

PMID: 35503246

PMCID: 9115651

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.